02:03:51 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-13 Bokslutskommuniké 2024
2024-10-24 Kvartalsrapport 2024-Q3
2024-08-15 Kvartalsrapport 2024-Q2
2024-05-23 Ordinarie utdelning VIMIAN 0.00 SEK
2024-05-22 Årsstämma 2024
2024-05-02 Kvartalsrapport 2024-Q1
2024-02-15 Bokslutskommuniké 2023
2023-11-08 Kvartalsrapport 2023-Q3
2023-08-17 Kvartalsrapport 2023-Q2
2023-06-02 Årsstämma 2023
2023-06-02 Ordinarie utdelning VIMIAN 0.00 SEK
2023-05-04 Kvartalsrapport 2023-Q1
2023-03-24 Extra Bolagsstämma 2023
2023-03-08 Bokslutskommuniké 2022
2022-11-16 Kvartalsrapport 2022-Q3
2022-10-03 Extra Bolagsstämma 2022
2022-08-24 Kvartalsrapport 2022-Q2
2022-06-03 Ordinarie utdelning VIMIAN 0.00 SEK
2022-06-02 Årsstämma 2022
2022-05-24 Kvartalsrapport 2022-Q1
2022-03-09 Bokslutskommuniké 2021
2021-11-26 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Vimian Group är en koncern verksamma inom djurhälsa. Bolaget levererar via sina dotterbolag läkemedel och tekniska lösningar till veterinärer, laboratorier och husdjursägare. Produkterna inkluderar exempelvis läkemedel med tillhörande klinisk forskning samt digitala plattformar för veterinärkliniker. Bolaget är verksamma på en global nivå med huvudkontor i Stockholm.
2022-11-23 08:00:00

Colleen Flesher, currently COO Movora, has been appointed new Co-CEO of Movora, the operating company within Vimian’s MedTech segment. Colleen assumes her position on 1 December and succeeds Patrick Gendreau and Christopher Sidebotham who have decided to step down.

Colleen Flesher has more than twenty years of experience from leadership positions in the global MedTech sector. Colleen Flesher joined Movora as COO in October after three years as President & General Manager for Lima Corporate in the US, a leading provider of orthopedic implants to human healthcare. Prior to that she spent almost ten years at Johnson & Johnson’s MedTech divisions in various managerial positions within sales, marketing, product development and innovation.

Colleen assumes her position as Co-CEO of Movora and member of Vimian’s management team, alongside Co-CEO Guy Spörri, on 1 December. She succeeds Patrick Gendreau and Christopher Sidebotham who have decided to step down after more than thirty years as founders and leaders of Veterinary Orthopedic Implants (VOI) and Biomedtrix.

“I would like to sincerely thank Patrick and Chris who over the past thirty years have founded and grown two successful, leading orthopedics businesses in the US with remarkable commercial and innovation capabilities. I am thankful for their exceptional leadership throughout the integration into Vimian and the formation of Movora, today a global leader in veterinary orthopedics, says Dr. Fredrik Ullman, CEO of Vimian Group and continues:

“Colleen Flesher is a highly appreciated leader with significant experience from the MedTech sector. With Colleen onboard, we are now ready to take the next step in our succession plans for Movora. Together with Co-CEO Guy Spörri and the rest of the leadership team in Movora, we will continue to deliver on our strategic agenda strengthening and broadening our global position in veterinary MedTech”.

Colleen Flesher assumes her position as Co-CEO of Movora on 1 December. Christopher Sidebotham will remain in the company as senior advisor with focus on R&D and innovation.